Signal pathway profiling of prostate cancer using reverse phase protein arrays

被引:139
作者
Grubb, RL
Calvert, VS
Wulkuhle, JD
Paweletz, CP
Linehan, WM
Phillips, JL
Chuaqui, R
Valasco, A
Gillespie, J
Emmert-Buck, M
Liotta, LA
Petricoin, EF
机构
[1] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA
[2] NCI, Urol Oncol Branch, Bethesda, MD 20892 USA
[3] NCI, Ctr Canc Res, Pathol Lab, FDA Clin Proteom Program, Bethesda, MD 20892 USA
[4] NCI, Pathol Lab, Clin Pathogenet Unit, Bethesda, MD 20892 USA
[5] Catholic Univ Chile, Dept Urol, Santiago, Chile
关键词
prostate cancer; protein microarrays; signal transduction profiling;
D O I
10.1002/pmic.200300598
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Reverse phase protein arrays represent a new proteomics microarray technology with which to study the fluctuating state of the proteome in minute quantities of cells. The activation status of cell signaling pathways controls cellular fate and deregulation of these pathways underpins carcinogenesis. Changes in pathway activation that occur between early stage prostatic epithelial lesions, prostatic stroma and the extracellular matrix can be analyzed by obtaining pure populations of cell types by laser capture microdissection (LCM) and analyzing the relative states of several key phosphorylation points within the cellular circuitry. We have applied reverse phase protein array technology to analyze the status of key points in cell signaling involved in pro-survival, mitogenic, apoptotic and growth regulation pathways in the progression from normal prostate epithelium to invasive prostate cancer. Using multiplexed reverse phase protein arrays coupled with LCM, the states of signaling changes during disease progression from prostate cancer study sets were analyzed. Focused analysis of phosphospecific endpoints revealed changes in cellular signaling events through disease progression and, between patients. We have used a new protein array technology to study specific molecular pathways believed to be important in cell survival and progression from normal epithelium to invasive carcinoma directly from human tissue specimens. With the advent of molecular targeted therapeutics, the identification, characterization and monitoring of the signaling events within actual human biopsies will be critical for patient-tailored therapy.
引用
收藏
页码:2142 / 2146
页数:5
相关论文
共 20 条
[1]   Growth factors and their receptors: New targets for prostate cancer therapy [J].
Barton, J ;
Blackledge, G ;
Wakeling, A .
UROLOGY, 2001, 58 (2A) :114-122
[2]  
BRAWLEY OW, 2000, COMPREHENSIVE TXB GE, P533
[3]   Rationale for earlier and less frequent prostate cancer screening [J].
Carter, HB .
UROLOGY, 2001, 58 (05) :639-641
[4]  
DAmico AV, 2002, Campbell's urology, V8th, P3147
[5]   Delineation of prognostic biomarkers in prostate cancer [J].
Dhanasekaran, SM ;
Barrette, TR ;
Ghosh, D ;
Shah, R ;
Varambally, S ;
Kurachi, K ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2001, 412 (6849) :822-826
[6]  
EASTHAM JA, 2002, CAMPBELLS UROLOGY, P3080
[7]   Laser capture microdissection [J].
EmmertBuck, MR ;
Bonner, RF ;
Smith, PD ;
Chuaqui, RF ;
Zhuang, ZP ;
Goldstein, SR ;
Weiss, RA ;
Liotta, LA .
SCIENCE, 1996, 274 (5289) :998-1001
[8]   Anticancer drug targets: growth factors and growth factor signaling [J].
Gibbs, JB .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :9-13
[9]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[10]  
MOLLEY ED, 2003, HYPERTENSION, V41, P775